Hyalex Orthopaedics Strengthens Leadership Team

Mark Roby joins the company as the VP of R&D

News provided by

Hyalex Orthopaedics

25 Nov, 2019, 09:00 ET

BOSTON, Nov. 25, 2019 /PRNewswire/ -- Hyalex Orthopaedics, Inc., a medical device company developing synthetic cartilage solutions for the orthopaedics market, today announced that Mark Roby, PhD has joined the company as its VP of R&D.  Roby, an experienced medical device industry executive known for building high-performing teams and delivering results was most recently CEO of BI Medical.

"Mark's strategic acumen and proven track record of leadership delivering over 25 complex and innovative medical surgical products to market made him the ideal choice to lead our R&D organization," said Mira Sahney, Hyalex President and CEO.  Additionally, he is an inventor on over 50 patents in the areas of polymers and adhesives.  "We are pleased to have Mark join our company as we work to bring our novel technology platform into the clinic and the marketplace."

Roby joins Hyalex following a successful career in R&D leadership positions with Bard, Covidien, Salient Surgical (acquired by Medtronic) and US Surgical in addition to leadership roles including production, quality, clinical, marketing and sales.  "I'm excited for the opportunity to lead such an exceptional team of innovators and product developers through the next phase of growth for the company," Roby said.  "Implant systems we are developing based on the HYALEX synthetic cartilage technology have the potential to positively impact patient treatment outcomes and transform orthopaedics."

About Hyalex Orthopaedics, Inc.
Hyalex Orthopaedics is a Lexington, MA medical device company dedicated to improving quality of life for patients with cartilage injury and disease, such as osteoarthritis.  Hyalex is developing new implant systems that feature the HYALEX™ materials technology, a polymer system that is designed to mimic cartilage.  The company's vision is to provide an upstream solution in the care continuum prior to conventional total joint replacement surgery.  Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.  For more information about Hyalex Orthopaedics, follow the company on LinkedIn.

Contact:
William Nevius
[email protected]

SOURCE Hyalex Orthopaedics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.